ZA783492B - Cyclic amino acids - Google Patents

Cyclic amino acids

Info

Publication number
ZA783492B
ZA783492B ZA00783492A ZA783492A ZA783492B ZA 783492 B ZA783492 B ZA 783492B ZA 00783492 A ZA00783492 A ZA 00783492A ZA 783492 A ZA783492 A ZA 783492A ZA 783492 B ZA783492 B ZA 783492B
Authority
ZA
South Africa
Prior art keywords
amino acids
cyclic amino
cyclic
acids
amino
Prior art date
Application number
ZA00783492A
Other languages
English (en)
Inventor
E Falch
Larsen P Krogsgaard
Original Assignee
E Falch
Larsen P Krogsgaard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E Falch, Larsen P Krogsgaard filed Critical E Falch
Publication of ZA783492B publication Critical patent/ZA783492B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
ZA00783492A 1977-06-20 1978-06-19 Cyclic amino acids ZA783492B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2574077 1977-06-20

Publications (1)

Publication Number Publication Date
ZA783492B true ZA783492B (en) 1979-06-27

Family

ID=10232513

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA00783493A ZA783493B (en) 1977-06-20 1978-06-19 Improvement in or relating to heterocyclic compounds
ZA00783492A ZA783492B (en) 1977-06-20 1978-06-19 Cyclic amino acids

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA00783493A ZA783493B (en) 1977-06-20 1978-06-19 Improvement in or relating to heterocyclic compounds

Country Status (14)

Country Link
US (2) US4278676A (xx)
EP (4) EP0028017A1 (xx)
JP (2) JPS5436275A (xx)
AT (1) AT368505B (xx)
AU (2) AU3724478A (xx)
CA (1) CA1107736A (xx)
DK (2) DK270278A (xx)
ES (2) ES470912A1 (xx)
FI (2) FI64376C (xx)
IE (1) IE47200B1 (xx)
IT (2) IT7868449A0 (xx)
NO (3) NO152049C (xx)
NZ (1) NZ187615A (xx)
ZA (2) ZA783493B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145473A1 (de) * 1980-11-27 1982-08-26 Kefalas A/S, Koebenhavn-Valby 2-substituierte 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-on-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3145474A1 (de) * 1980-11-27 1982-09-02 Kefalas A/S, Koebenhavn-Valby 3-substituierte 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0083378A1 (en) * 1981-12-22 1983-07-13 Chugai Seiyaku Kabushiki Kaisha Tetrahydronicotinamide derivatives, a process for producing the same and a pharmaceutical composition comprising the same
GB8314391D0 (en) * 1983-05-24 1983-06-29 Kefalas As Heterocyclic compounds
IT1228426B (it) * 1987-07-20 1991-06-17 Ausimont Spa Perossiacidi eterociclici
US4859666A (en) * 1988-07-06 1989-08-22 Bristol-Myers Company THAZ derivatives for enhancement of cerebral function
CN1043051C (zh) * 1994-07-22 1999-04-21 国际壳牌研究有限公司 制备氢化石蜡的方法
ES2341004T3 (es) 2003-06-25 2010-06-14 H. Lundbeck A/S Gaboxadol para tratar la depresion y otros trastornos afectivos.
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
ES2515092T3 (es) * 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
WO2005079851A2 (en) * 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
WO2006118897A1 (en) * 2005-04-29 2006-11-09 H.Lundbeck A/S Acid and base salt forms of gaboxadol
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100193652A1 (en) * 2009-02-02 2010-08-05 William Stajos Wall Display System And Method Of Providing The Same
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (zh) * 2014-04-11 2015-10-14 天津药物研究院 一种氨甲基羟异恶唑类似物的制备方法
US20150352085A1 (en) 2014-06-06 2015-12-10 Ovid Therapeutics Inc. Methods of increasing tonic inhibition and treating secondary insomnia
WO2016150953A1 (en) * 2015-03-24 2016-09-29 H. Lundbeck A/S Manufacture of 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
WO2019028234A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
CA3120856A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics, Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114292224B (zh) * 2022-03-07 2022-05-20 中国农业科学院农产品加工研究所 一种大麻二酚-2-（n-乙酰基）哌啶酸酯及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784190A (en) * 1952-03-28 1957-03-05 Upjohn Co Alkyl piperidinepropionates
CA762455A (en) * 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
US3381016A (en) * 1966-03-04 1968-04-30 Upjohn Co Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (de) * 1972-05-04 1973-11-15 Bayer Ag Verfahren zur herstellung von tetrahydropyridinen
DK62791A (da) * 1991-04-09 1992-11-09 Tulip Int As Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden

Also Published As

Publication number Publication date
NZ187615A (en) 1981-12-15
JPS5436275A (en) 1979-03-16
NO152049C (no) 1985-07-24
EP0000338A3 (en) 1979-06-27
IT1159739B (it) 1987-03-04
ZA783493B (en) 1979-06-27
ATA448678A (de) 1982-02-15
US4301287A (en) 1981-11-17
AU521040B2 (en) 1982-03-11
DK270378A (da) 1978-12-21
EP0000167A1 (en) 1979-01-10
FI781954A (fi) 1978-12-21
EP0028017A1 (en) 1981-05-06
EP0000338A2 (en) 1979-01-24
FI64376B (fi) 1983-07-29
AT368505B (de) 1982-10-25
AU3724478A (en) 1980-01-03
EP0000338B1 (en) 1981-11-25
ES470913A1 (es) 1979-02-01
DK270278A (da) 1978-12-21
IT7868449A0 (it) 1978-06-20
NO782128L (no) 1978-12-21
AU3729878A (en) 1980-01-03
FI781955A (fi) 1978-12-21
FI64376C (fi) 1983-11-10
IE47200B1 (en) 1984-01-11
NO792839L (no) 1978-12-21
CA1107736A (en) 1981-08-25
US4278676A (en) 1981-07-14
EP0027279A1 (en) 1981-04-22
IT7868450A0 (it) 1978-06-20
NO152049B (no) 1985-04-15
ES470912A1 (es) 1979-02-01
IE781234L (en) 1978-12-20
JPS5436290A (en) 1979-03-16
NO782127L (no) 1978-12-21

Similar Documents

Publication Publication Date Title
ZA783492B (en) Cyclic amino acids
JPS5488291A (en) Substituteddpenn22mmcarboxylic acids
NZ186679A (en) 7-substituted-3-cephem-4-carboxylic acids
JPS53130617A (en) 2 ajido 2 deokishigurikoshirunitoreetomataha haraidooyobisonoseizoho 2 amino mataha2 asetoamido gurikoosunoseizoho oyobigurikoshidooyobisonoseizohoho narabinigaigurikoshidoyorinarumenekikyuchakutai
PH16587A (en) Fluorinated amino acids
AU4258178A (en) Peptide derivatives
CA1109861A (en) 2-methylpenem-3-carboxylic acids
HK27984A (en) 1-azaxanthone-3-carboxylic acids
NZ187534A (en) Ethynyl - aminoacetic acids
ZA783699B (en) Peptides
HK18184A (en) Fluorinated amino acids
ZA783353B (en) A-acetylenic amino acid derivatives
JPS5398983A (en) Oreandomycine 44substituted amino derivative
GB2001958B (en) Mercaptoacylamidobenzoyl glycine
IL54913A0 (en) -halomethyl amino acids
GB2001309B (en) Alpha-halomethyl amino acid derivatives
GB2001626B (en) Alpha-halomethyl dericatives of amino acids
GB2001061B (en) -vincly amino acids
ZA783368B (en) A-vinyl amino acid derivatives
JPS52153946A (en) Cyclic amino acid
GB2006800B (en) Aliphatic polyamides
GB2001060B (en) A-acetylenic amino acids
AU3592478A (en) Acids 5-alkylsulphonyl- and 5-alkenylsulphonylbarbituric
IL59481A0 (en) -halomethyl amino acids
JPS5287142A (en) New cyclic amino acid